ILGEN employs a cutting-edge technology focused on the efficient generation, selection, and expansion of high-affinity fully human monoclonal antibodies. This innovative approach is designed to produce antibodies with neutralizing activity and unique amino acid structures, significantly minimizing potential immune responses that can arise from nonhuman components. The technology enables the rapid detection and generation of specific high-affinity human antibodies for various therapeutic and diagnostic applications, including cancer treatment and a range of other conditions such as infections and autoimmune diseases. Notably, ILGEN's method drastically reduces the typical turnaround time for obtaining functionally validated antibodies from 1-2 years to just 6 months.

One of the key advancements in ILGEN's pipeline is the development of the Anti-LAG-3 antibody, a fully human antibody targeting the LAG-3 receptor, which plays a crucial role in immune regulation and cancer treatment. This antibody represents a new generation of immune checkpoint inhibitors, which have transformed cancer therapy. Additionally, ILGEN is working on a fully human fusion protein, ILG-F, aimed at treating erectile dysfunction by promoting revascularization in patients with vasculogenic ED. This innovative approach addresses limitations of existing treatments, such as PDE5 inhibitors, by targeting the underlying endothelial dysfunction. Overall, ILGEN's proprietary technologies hold promise for advancing antibody-based therapies and improving patient outcomes across various medical conditions.

United States

ILGEN is a biopharmaceutical company propelling medicine on novel proprietary biotechnology. They are the first-in-class, naturally occurring LAG3 checkpoint inhibitor.

ILGEN

Company Details